Pharmaceutical manufacturers routinely fund independent charity patient assistance programs that cover Medicare patients' copays and deductibles. The arrangement is lawful when the charity is genuinely independent of the donor. It becomes a federal enforcement target when the donor controls, directly or through a specialty pharmacy or data-sharing arrangement, which patients on which drugs actually receive the assistance. The Department of Justice and HHS Office of Inspector General (OIG) have pursued this exact fact pattern for over a decade, and the resulting settlements define, in dollar terms, exactly where the independence line sits. Physicians who refer patients into these programs, or whose practices participate in manufacturer-funded assistance, should understand where OIG draws that line before a subpoena arrives.
The Independence Requirement OIG Built
OIG's guidance on independent charity patient assistance programs runs through two documents: a 2005 Special Advisory Bulletin on assistance for Medicare Part D enrollees, and a 2014 Supplemental Special Advisory Bulletin that sharpened the rules on disease funds, eligible recipients, and donor conduct. The core requirement in both: the charity's decisions about who gets help must be made independently of the donor. A manufacturer may earmark a donation for a broad disease category, but OIG has flagged charities that define their disease funds so narrowly, by specific symptom, severity, or drug delivery method, that the fund effectively subsidizes only the donor's own product. Donors also cannot receive data that would let them identify which of their own patients the charity is assisting, because that data flow lets a manufacturer steer its own donation back to its own drug through the foundation as an intermediary.
The Settlements That Defined the Limits
The Anti-Kickback Statute (AKS) prohibits a manufacturer from offering remuneration, including a patient's copay, to induce the purchase of its own drug, whether the payment reaches the patient directly or through a foundation. In October 2024, Teva Pharmaceuticals USA Inc. and Teva Neuroscience Inc. agreed to pay $450 million to resolve two civil matters alleging AKS and civil False Claims Act (FCA) violations tied to its multiple sclerosis drug Copaxone. DOJ alleged Teva coordinated with a specialty pharmacy and two nominally independent copay foundations to route donations specifically toward covering Copaxone patients' Medicare copays, while raising the drug's price. This was a civil settlement of allegations, not a criminal conviction; Teva did not plead guilty to a crime. Earlier, in April 2019, Astellas Pharma US Inc. and Amgen Inc. agreed to pay a combined $124.75 million to resolve similar civil FCA allegations that each company used a purportedly independent foundation to cover Medicare copays for its own drugs.
Every settlement in this line traces back to the same defect: a donor that could see, shape, or narrow which patients on which drugs received foundation assistance was no longer funding an independent charity. It was funding its own sales channel.
Why This Reaches Physicians and Practices
These cases target manufacturers directly, but the enforcement theory reaches further. A practice that refers patients to a specific foundation at a manufacturer's suggestion, that receives marketing materials tying a foundation's assistance to a single branded drug, or that participates in a specialty pharmacy's copay-routing workflow can become a fact witness, and in some postures a co-defendant, when DOJ examines whether the arrangement was steering. The government's civil investigative demand authority under the FCA extends to any entity with relevant records, not only the manufacturer. A physician practice that received a CID or a grand jury subpoena tied to a copay assistance investigation is being asked to produce referral patterns, foundation communications, and prescribing data that the government will use to test independence, whether or not the practice is a target.
Why Early Legal Counsel Is Critical
It is critical that healthcare providers promptly retain experienced healthcare defense counsel upon receiving a subpoena, audit notice, investigative request, or other government inquiry. Early legal intervention can protect the provider's rights, ensure appropriate responses to government requests, avoid inadvertent admissions, preserve relevant defenses, and allow counsel to communicate with investigators on the provider's behalf. Delaying legal representation can significantly affect the outcome of a matter and expose the provider to unnecessary risk.
How Health Law Alliance Can Help
Health Law Alliance represents physicians and practices facing federal inquiries into copay assistance arrangements, kickback allegations, and related Stark Law exposure, with 25+ years of combined experience across 5,000+ matters. If your practice has received a subpoena, CID, or other inquiry tied to a manufacturer-funded assistance program, contact us for a free, confidential consultation.
